Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Universidad de Castilla-La Mancha, Health and Social Research Center, Cuenca, Spain.
Adv Nutr. 2019 May 1;10(suppl_2):S212-S223. doi: 10.1093/advances/nmz014.
Milk and dairy product consumption has been associated with an increase in prostate cancer risk; however, discrepancies have been observed in the literature. This first overview of systematic reviews and meta-analyses was carried out with the main objective of compiling and discussing the evidence generated to date related to milk and dairy product consumption and prostate cancer risk and mortality. A systematic search in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and the Web of Science (from inception to 30 April 2018) was conducted. The inclusion criteria were as follows: adult men, meta-analyses of longitudinal studies, dairy product consumption, and risk of prostate cancer or related outcomes. The AMSTAR2 checklist was used to evaluate methodological quality. The synthesis methods included dairy product exposure (high compared with low consumption or dose-response), dairy product type (total dairy products, milk, cheese, yogurt, and others), and prostate cancer outcomes (total, nonadvanced, and advanced prostate cancer and mortality) displayed in forest plots. Six meta-analyses were identified. These studies reported on the analysis of the 2 to 32 cohorts (up to 848,395 subjects/38,107 cases; 4-28 y of follow-up) and 2 case-control meta-analyses (12,435 subjects). The meta-analysis quality was valued as mostly "good" according to the AMSTAR2 criteria. All RRs of high compared with low consumption (dose-response) for total prostate cancer ranged from 1.68 to 1.09 (1.07 per 400 g/d) for total dairy products, 1.50 to 0.92 (1.06 to 0.98 per 200 g/d) for milk (whole, low-fat, and skim milk considered separately), and 1.18 to 0.74 (1.10 per 50 g/d) for cheese. RRs have decreased since the first meta-analysis. Statistical heterogeneity generates uncertainty in the observed results (up to I2 = 77.1%). In conclusion, although there are some data indicating that higher consumption of dairy products could increase the risk of prostate cancer, the evidence is not consistent. This review was registered with PROSPERO as CRD42018094737.
牛奶和乳制品的消费与前列腺癌风险的增加有关;然而,文献中存在差异。本研究首次对系统评价和荟萃分析进行了综述,主要目的是对迄今为止与牛奶和乳制品消费与前列腺癌风险和死亡率相关的证据进行汇编和讨论。在 MEDLINE、EMBASE、Cochrane 中央对照试验注册库、Cochrane 系统评价数据库和 Web of Science(从开始到 2018 年 4 月 30 日)中进行了系统搜索。纳入标准如下:成年男性、队列研究的荟萃分析、乳制品消费、前列腺癌或相关结局的风险。使用 AMSTAR2 清单评估方法学质量。综合方法包括乳制品暴露(高与低消费或剂量反应)、乳制品类型(总乳制品、牛奶、奶酪、酸奶和其他)以及前列腺癌结局(总前列腺癌、非进展性前列腺癌和进展性前列腺癌和死亡率),以森林图显示。确定了六项荟萃分析。这些研究报告了对 2 至 32 项队列研究(最多 848395 名受试者/38107 例;4-28 年随访)和 2 项病例对照荟萃分析(12435 名受试者)的分析。根据 AMSTAR2 标准,荟萃分析质量被评估为“良好”。与低消费(剂量反应)相比,总前列腺癌的所有 RR 范围为 1.68 至 1.09(每 400g/d 增加 1.07),总乳制品;1.50 至 0.92(每 200g/d 增加 1.06 至 0.98),牛奶(全脂、低脂和脱脂牛奶分别考虑)和 1.18 至 0.74(每 50g/d 增加 1.10),奶酪。自第一次荟萃分析以来,RR 有所下降。统计异质性给观察结果带来了不确定性(高达 I2=77.1%)。总之,尽管有一些数据表明,较高的乳制品消费可能会增加前列腺癌的风险,但证据并不一致。本综述已在 PROSPERO 中注册,注册号为 CRD42018094737。